

In the Claims:

1. (currently amended) A mutated polypeptide derived from the pollen allergen Phl p 7, said polypeptide selected from the group consisting of the sequences as shown in SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6, whereby said polypeptide has a reduced allergenic activity compared to wild type Phl p 7.
2. (original) A polypeptide according to claim 1 which is capable of inducing an IgG response in a mammal.
3. (original) A polypeptide according to claim 1 or 2 which induces a histamine release which is significantly reduced compared with wild type Phl p 7.
4. (original) A polynucleotide encoding a polypeptide according to claim 1.
5. (original) A vector or plasmid containing a polynucleotide according to claim 4.
6. (original) A host cell transformed or transfected with a vector or a plasmid according to claim 5.
7. (currently amended) A method of preparing a polypeptide ~~according to any one of claim 1 to 3~~ comprising culturing host cells according to claim 6 under conditions that said polypeptide is expressed and optionally recovering said polypeptide from said host cells.
8. (currently amended) A method of preparing a polypeptide according to claim[[s]] 1 ~~to 3~~ comprising chemically synthesizing said polypeptide.

Claims 9-13 (canceled).

14. (currently amended) A pharmaceutical composition comprising a polypeptide according to ~~any one of claim[[s]] 1 to 3~~ and a pharmaceutically acceptable carrier or diluent.
15. (currently amended) A ~~pharmaceutical~~ kit comprising a polypeptide according to claim[[s]] 1 ~~to 3 or a pharmaceutical composition according to claim 14 and a~~ pharmaceutically acceptable carrier or diluent.

16. (new) A method of treating and/or preventing an allergic disorder, said method comprising administering to a patient in need thereof an effective amount of the polypeptide of claim 1.

17. (new) The method of claim 16, wherein said allergic disorder is an allergy to a two-EF hand pollen allergen.

18. (new) The method of claim 17, wherein said disorder is allergy to Phl p 7.

19. (new) The method of claim 17, wherein the allergic disorder is allergy to an allergen selected from the group consisting of Bet v 4, Bra r 1, Aln g 4, Bra n 1, Cyn d 7, Ole e 3, Syr v 3 and/or Phl p 7.